Apogee Therapeutics’ $135.11/Share AbbVie Acquisition Faces Fiduciary Duty Investigation
APGE•Apogee Therapeutics is under investigation by Halper Sadeh LLC over its sale to AbbVie for $135.11 per share in cash, citing alleged breaches of securities laws and fiduciary duties. The firm warns deal terms may limit competing bids and urges shareholders to seek legal options on a contingent fee basis.
1. Sale to AbbVie Terms
Apogee Therapeutics agreed to sell all outstanding shares to AbbVie for $135.11 per share in cash, reflecting a valuation premium over recent market levels and completing a $10.9 billion transaction.
2. Legal Investigation Details
Halper Sadeh LLC is probing the merger for potential violations of federal securities laws and breaches of fiduciary duties, with particular focus on whether the deal restricts superior competing offers or involves undisclosed conflicts.
3. Shareholder Advisory
The law firm is urging Apogee shareholders to evaluate their rights and consider contingent-fee legal action to pursue increased consideration, additional disclosures or other relief without upfront costs.
